Naxitamab
Danyelza (naxitamab) is a monoclonal antibody medication used to treat high-risk neuroblastoma in children (1 year and older) and adults. It works by targeting GD2, a substance found on the surface of neuroblastoma cancer cells, helping the immune system recognize and destroy these cells. This medication is administered intravenously, typically in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), and is used for patients who have shown some response to prior treatment.
Danyelza is a targeted monoclonal antibody used to treat high-risk neuroblastoma by helping the immune system attack cancer cells.
Key facts at a glance
- RxNorm
- 2474240
- Generic
- Danyelza
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Treatment of high-risk neuroblastoma in patients 1 year of age and older who have shown partial response, minor response, or stable disease following prior therapy. Used in combination with GM-CSF.
Danyelza is a monoclonal antibody that specifically binds to GD2, a ganglioside antigen expressed on the surface of neuroblastoma cells. This binding helps the immune system recognize and destroy the cancer cells through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity.
Requires pre-medication for pain management and infusion reactions. Can cause serious side effects including severe pain, infusion-related reactions, peripheral neuropathy, and hyponatremia. Patients should be monitored closely during and after infusion. Treatment should be administered by healthcare professionals experienced in cancer immunotherapy.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy